From the Journals

Study finds sharp drop in opioid scripts among most specialties


 

What’s missing

Maya Hambright, MD, a family medicine physician in New York’s Hudson Valley, who has been working mainly in addiction in response to the opioid overdose crisis, observed that the drop in total prescribed volume of prescription painkillers does not necessarily translate into a reduction in use of opioids

“No one is taking fewer opioids,” Dr. Hambright told this news organization. “I can say that comfortably. They are just getting them from other sources.”

CDC data support Dr. Hambright’s view.

An estimated 100,306 people in the United States died of a drug overdose in the 12 months that ended in April 2021, an increase of 28.5% from the 78,056 deaths during the same period the year before, according to the CDC.

Dr. Hambright said more physicians need to be involved in prescribing medication-assisted treatment (MAT).

The federal government has in the past year loosened restrictions on a requirement, known as an X waiver. Certain clinicians have been exempted from training requirements, as explained in the frequently asked questions page on the Substance Abuse and Mental Health Services Administration website.

SAMHSA says legislation is required to eliminate the waiver. As of Dec. 30, 2021, more than half of the members of the U.S. House of Representatives were listed as sponsors of the Mainstreaming Addiction Treatment (MAT) Act (HR 1384), which would end the need for X waivers. The bill has the backing of 187 Democrats and 43 Republicans.

At this time, too many physicians shy away from offering MAT, Dr. Hambright said.

“People are still scared of it,” she said. “People don’t want to deal with addicts.”

But Dr. Hambright said it’s well worth the initial time invested in having the needed conversations with patients about MAT.

“Afterwards, it’s so straightforward. People feel better. They’re healthier. It’s amazing,” she said. “You’re changing lives.”

The research was supported by grants from the National Institutes of Health. Dr. Stein and coauthors reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA approves combo pill for severe, acute pain
MDedge Neurology
DIY nerve stimulation effective in episodic migraine
MDedge Neurology
Patients given NSAIDs over antiemetics for headaches spend less time in the ED
MDedge Neurology
Small fiber neuropathy is rising in the U.S., but why is a mystery
MDedge Neurology
Erenumab beats topiramate for migraine in first head-to-head trial
MDedge Neurology
Neurologist guilty of overprescribing thousands of doses of painkillers
MDedge Neurology
Are newer migraine therapies better? It depends
MDedge Neurology
Ginger for migraine: A new review
MDedge Neurology
Califf plans work on opioids, accelerated approvals on return to FDA
MDedge Neurology
AAN updates treatment guidance on painful diabetic neuropathy
MDedge Neurology